Literature DB >> 23237916

Kynurenines in the CNS: recent advances and new questions.

László Vécsei1, Levente Szalárdy, Ferenc Fülöp, József Toldi.   

Abstract

Various pathologies of the central nervous system (CNS) are accompanied by alterations in tryptophan metabolism. The main metabolic route of tryptophan degradation is the kynurenine pathway; its metabolites are responsible for a broad spectrum of effects, including the endogenous regulation of neuronal excitability and the initiation of immune tolerance. This Review highlights the involvement of the kynurenine system in the pathology of neurodegenerative disorders, pain syndromes and autoimmune diseases through a detailed discussion of its potential implications in Huntington's disease, migraine and multiple sclerosis. The most effective preclinical drug candidates are discussed and attention is paid to currently under-investigated roles of the kynurenine pathway in the CNS, where modulation of kynurenine metabolism might be of therapeutic value.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237916     DOI: 10.1038/nrd3793

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  223 in total

1.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress.

Authors:  R Lugo-Huitrón; T Blanco-Ayala; P Ugalde-Muñiz; P Carrillo-Mora; J Pedraza-Chaverrí; D Silva-Adaya; P D Maldonado; I Torres; E Pinzón; E Ortiz-Islas; T López; E García; B Pineda; M Torres-Ramos; A Santamaría; V Pérez-De La Cruz
Journal:  Neurotoxicol Teratol       Date:  2011-07-13       Impact factor: 3.763

2.  IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.

Authors:  G J Guillemin; S J Kerr; L A Pemberton; D G Smith; G A Smythe; P J Armati; B J Brew
Journal:  J Interferon Cytokine Res       Date:  2001-12       Impact factor: 2.607

3.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.

Authors:  P Winn; T W Stone; M Latimer; M H Hastings; A J Clark
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

5.  Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.

Authors:  P Guidetti; P H Reddy; D A Tagle; R Schwarcz
Journal:  Neurosci Lett       Date:  2000-04-14       Impact factor: 3.046

6.  Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Authors:  Holly K Koblish; Michael J Hansbury; Kevin J Bowman; Gengjie Yang; Claire L Neilan; Patrick J Haley; Timothy C Burn; Paul Waeltz; Richard B Sparks; Eddy W Yue; Andrew P Combs; Peggy A Scherle; Kris Vaddi; Jordan S Fridman
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

7.  Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives.

Authors:  N Eguchi; Y Watanabe; K Kawanishi; Y Hashimoto; O Hayaishi
Journal:  Arch Biochem Biophys       Date:  1984-08-01       Impact factor: 4.013

8.  Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels.

Authors:  Ross Grant; Vimal Kapoor
Journal:  Biochem Pharmacol       Date:  2003-09-15       Impact factor: 5.858

9.  Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.

Authors:  D Jauch; E M Urbańska; P Guidetti; E D Bird; J P Vonsattel; W O Whetsell; R Schwarcz
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

10.  1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats.

Authors:  Piotr Luchowski; Elzbieta Luchowska; Waldemar A Turski; Ewa M Urbanska
Journal:  Neurosci Lett       Date:  2002-09-13       Impact factor: 3.046

View more
  177 in total

1.  Biosynthesis of l-4-Chlorokynurenine, an Antidepressant Prodrug and a Non-Proteinogenic Amino Acid Found in Lipopeptide Antibiotics.

Authors:  Hanna Luhavaya; Renata Sigrist; Jonathan R Chekan; Shaun M K McKinnie; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2019-05-13       Impact factor: 15.336

2.  The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism.

Authors:  Jose Felix Martí-Massó; Alberto Bergareche; Vladimir Makarov; Javier Ruiz-Martinez; Ana Gorostidi; Adolfo López de Munain; Juan Jose Poza; Pasquale Striano; Joseph D Buxbaum; Coro Paisán-Ruiz
Journal:  J Mol Med (Berl)       Date:  2013-08-20       Impact factor: 4.599

3.  Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study.

Authors:  Abhishek Wadhawan; Aline Dagdag; Allyson Duffy; Melanie L Daue; Kathy A Ryan; Lisa A Brenner; John W Stiller; Toni I Pollin; Maureen W Groer; Xuemei Huang; Christopher A Lowry; Braxton D Mitchell; Teodor T Postolache
Journal:  Pteridines       Date:  2017-11-22       Impact factor: 0.581

4.  Kynurenine is correlated with IL-1β in plasma of schizophrenia patients.

Authors:  Helena P G Joaquim; Alana C Costa; Wagner F Gattaz; Leda Leme Talib
Journal:  J Neural Transm (Vienna)       Date:  2018-01-06       Impact factor: 3.575

5.  Quaternary structure of α-amino-β-carboxymuconate-ϵ-semialdehyde decarboxylase (ACMSD) controls its activity.

Authors:  Yu Yang; Ian Davis; Tsutomu Matsui; Ivan Rubalcava; Aimin Liu
Journal:  J Biol Chem       Date:  2019-06-12       Impact factor: 5.157

6.  Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.

Authors:  Vincent Chouraki; Sarah R Preis; Qiong Yang; Alexa Beiser; Shuo Li; Martin G Larson; Galit Weinstein; Thomas J Wang; Robert E Gerszten; Ramachandran S Vasan; Sudha Seshadri
Journal:  Alzheimers Dement       Date:  2017-06-08       Impact factor: 21.566

7.  Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD.

Authors:  Ludovic Belle; Vivian Zhou; Kara L Stuhr; Margaret Beatka; Emily M Siebers; Jennifer M Knight; Michael W Lawlor; Casey Weaver; Misato Hashizume; Cecilia J Hillard; William R Drobyski
Journal:  JCI Insight       Date:  2017-07-20

8.  Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance.

Authors:  Joshua Chiappelli; Ana Pocivavsek; Katie L Nugent; Francesca M Notarangelo; Peter Kochunov; Laura M Rowland; Robert Schwarcz; L Elliot Hong
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

Review 9.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

10.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.